510(k) Report

FDA product code · Ophthalmic

Photocoagulator And Accessories

HQBClass II21 CFR 886.4690510(k) required30 decisions since 197630 recalls

30 FDA decisions since 1976. 510(k) reviews decided 2021–2025 took a median of 276 days (half between 276 and 276). 30 recalls name this code, 0 of them Class I. The most-cited predicate is K111493, named by 3 later devices.

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026 Download the data (CSV)

FIG. A — Illustration, ophthalmic panel

Twenty years of HQB at a glance: how often FDA decides these devices, how long 510(k) reviews take, how often they are recalled, and how many adverse event reports name the code.

FDA decisions per year · HQB

1in 2022

2011: 32012: 12013: 32019: 22022: 1
2007high 3 (2011) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · HQB

221in 2013

2011: 57 days median2013: 221 days median
2007high 221 (2013) · low 57 (2011)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · HQB

2in 2025

2013: 282025: 2
2007high 28 (2013) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · HQB

7in 2025

2011: 32012: 32013: 22014: 12016: 12017: 22018: 32019: 12020: 142021: 12022: 32023: 32024: 32025: 7
2007high 14 (2020) · low 0 (2007)2025

MAUDE reports naming product code HQB, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
201135703
20121—03
20133221282
20140—01
20150—00
20160—01
20170—02
20180—03
20192—01
20200—014
20210—01
20221—03
20230—03
20240—03
20250—27
20260—0—
FIG. 1 — HQB by year, 2007–2026Sources: FDA decision databases, recall and enforcement reports, MAUDE · Data through Oct 25, 2026

Planning a device in HQB? A 510(k) Report ranks candidate predicates in this code by lineage, citations and recall history, with the review-time outlook.

See the 510(k) Report